A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

← catalyst calendar

NCT06625060 · readout in 438 d

Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

641estimated

Sites

166

Countries

Australia, Brazil, Canada +11

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-10-10

actual

When the study began enrolling

Primary completion

2027-10-31

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-10-31

estimated

The whole study's end, after follow-up

First posted

2024-10-03

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-28

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Episodic Migraine
Chronic Migraine

Interventions

Biological: Corabotase
Other: Placebo
Biological: Corabotase dose A
Biological: Corabotase dose B

Primary outcomes

what the primary-completion date above is the date OF

Percentage of participants experiencing any Adverse Event (AEs) including treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse event of special interest (AESI) and AE leading to treatment discontinuation

measured For step 1: From baseline until end of study at Week 36

Percentage of Participants with clinically significant changes from baseline in Laboratory Parameters